U.S. FDA Approves ZEVASKYN(TM) (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Stock Information for Fortitude Gold Corp Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortitude Gold Corp Com

Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL(TM) Study Data in Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN(TM) Gene Therapy to Treat Wounds in Painful Skin Disorder
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.